3 Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan Pet al. Efﬁcacy and safety of exenatide once weekly versus sitag- liptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431–439. 4 DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, andcaloric intake: a randomized, cross-over study. Curr Med Res Opin 2008; 24: 2943–2952. 5 Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improvedglycemic control of type 2 diabetes. Regul Pept 2004; 117: 77– 88. 6 Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non- inferiority study. Lancet 2008; 372: 1240–1250.